Bill

Bill > HRes787


US HRes787

Providing for consideration of the bill (H.B. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.B. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with anoth


summary

Introduced
03/19/2018
In Committee
Crossed Over
Passed
Dead
12/31/2018

Introduced Session

115th Congress

Bill Summary

Providing for consideration of the bill (H.B. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.B. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes; and for other purposes. Sets forth the rule for consideration of the bill (H.B. 4566) to amend the Dodd-Frank Wall Street Reform and Consumer Protection Act to provide relief to nonbanks from certain stress test requirements under such Act; providing for consideration of the bill (H.B. 5247) to authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes.

Sponsors (1)

Last Action

Motion to reconsider laid on the table Agreed to without objection. (on 03/20/2018)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...